Wykoff CC, Abreu F, Adamis AP, Basu K, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet 2022 Jan 21. pii: S0140-6736(22)00018.
PMID: 35085503